Showing 341 - 360 results of 472 for search '"The University of Minnesota"', query time: 0.07s Refine Results
  1. 341
  2. 342
  3. 343
  4. 344
  5. 345
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350

    Ditch management using low-grade weirs: an opportunity for mitigating water quality and quantity impacts by J. S. Strock, A. Z. Ranaivoson

    Published 2025-01-01
    “…One control (without weirs) and one treatment (with weirs) ditch were studied from 2017 through 2023 at the University of Minnesota, Southwest Research and Outreach Center near Lamberton, MN, United States. …”
    Get full text
    Article
  11. 351
  12. 352
  13. 353
  14. 354
  15. 355
  16. 356

    Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation by Vera V, Sheybani A, Panarelli JF, Grover DS, Lee J, Craven ER, Samuelson TW, Ahmed IIK

    Published 2025-01-01
    “…Vanessa Vera,1 Arsham Sheybani,2 Joseph F Panarelli,3 Davinder S Grover,4 James Lee,5 Earl Randy Craven,2 Thomas W Samuelson,6 Iqbal Ike K Ahmed7 1Allergan, an AbbVie company, Irvine, CA, USA; 2Washington University School of Medicine, St Louis, MO, USA; 3Department of Ophthalmology, New York University Langone Health, New York, NY, USA; 4Glaucoma Associates of Texas, Dallas, TX, USA; 5Colorado Eye Institute, Colorado Springs, CO, USA; 6Minnesota Eye Consultants, University of Minnesota, Minneapolis, MN, USA; 7John Moran Eye Center, University of Utah, Salt Lake City, UT, USACorrespondence: James Lee, Colorado Eye Institute, Colorado Springs, CO, 80924, USA, Email jlee@eyescolorado.comAbstract: The XEN® 45 Glaucoma Treatment System (gel stent; Allergan, an AbbVie company, Irvine, CA, USA) is a minimally invasive bleb-forming surgical device that was originally approved to lower intraocular pressure by diverting the aqueous humor from the anterior chamber to the subconjunctival space (like trabeculectomy) following ab-interno placement. …”
    Get full text
    Article
  17. 357
  18. 358
  19. 359
  20. 360